#NIH clinical trial of investigational vaccine for #COVID_19 begins
![]() 3856 Friday, 27 March, 2020, 11:25 A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is funding the trial. KPWHRI is part of NIAID’s Infectious Diseases Clinical Research Consortium. The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks. The first participant received the investigational vaccine today. The study is evaluating different doses of the experimental vaccine for safety and its ability to induce an immune response in participants. This is the first of multiple steps in the clinical trial process for evaluating the potential benefit of the vaccine. |
Apple debuts iPhone 17
372Yesterday, 23:08Yuri Ivashechkin, the creator of the Su-25 attack aircraft, has died
109603.09.2025, 13:33Türkiye to build spaceport in Somalia for rocket, missile tests
290405.08.2025, 18:17A woman in India has been diagnosed with a unique blood type
380130.07.2025, 14:21Global media forum with Aliyev's participation to be held in occupied Stepanakert
468019.07.2025, 17:30SpaceX Starship rocket explodes during test flight (video)
688819.06.2025, 12:34Elon Musk announces XChat feature
772202.06.2025, 13:04The world's lowest car has been created in Taiwan (video)
918826.05.2025, 11:40